Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease

Takaomi Kessoku, Takashi Kobayashi, Anna Ozaki, Michihiro Iwaki, Yasushi Honda, Yuji Ogawa, Kento Imajo, Yusuke Saigusa, Koji Yamamoto, Takeharu Yamanaka, Haruki Usuda, Koichiro Wada, Masato Yoneda, Satoru Saito, Atsushi Nakajima, Takaomi Kessoku, Takashi Kobayashi, Anna Ozaki, Michihiro Iwaki, Yasushi Honda, Yuji Ogawa, Kento Imajo, Yusuke Saigusa, Koji Yamamoto, Takeharu Yamanaka, Haruki Usuda, Koichiro Wada, Masato Yoneda, Satoru Saito, Atsushi Nakajima

Abstract

Introduction: Non-alcoholic fatty liver disease (NAFLD) pathogenesis involves abnormal metabolism of cholesterol and hepatic accumulation of toxic free-cholesterol. Elobixibat (EXB) inhibits the ileal bile acid (BA) transporter. EXB and cholestyramine (CTM) facilitate the removal of free cholesterol from the liver by decreasing BA recirculation to the liver, thereby stimulating novel BA synthesis from cholesterol. In this randomised, double-blind, placebo-controlled, parallel-group, phase IIa study, we aim to provide a proof-of-concept assessment by evaluating the efficacy and safety of EXB in combination with CTM in patients with NAFLD.

Methods and analysis: A total of 100 adult patients with NAFLD, diagnosed based on low-density lipoprotein cholesterol (LDL-C) level of >120 mg/dL and liver fat content of ≥8% by MRI-based proton density fat fraction (MRI-PDFF), who meet the inclusion/exclusion criteria will be enrolled. The patients will be randomly assigned to receive the combination therapy of 10 mg EXB and 9 g CTM powder (4 g CTM), 10 mg EXB monotherapy, 9 g CTM powder monotherapy or a placebo treatment (n=25 per group). Blood tests and MRIs will be performed 16 weeks following treatment initiation. The primary study endpoint will be the absolute LDL-C level change at week 16 after treatment initiation. The exploratory endpoint will include absolute changes in the liver fat fraction as measured by MRI-PDFF. This proof-of-concept study will determine whether the combination therapy of EXB and CTM is effective and safe for patients with NAFLD.

Ethics and dissemination: Ethics approval was obtained from the Ethics Committee of Yokohama City University Hospital before participant enrolment. The results of this study will be submitted for publication in international peer-reviewed journals and the key findings will be presented at international scientific conferences.

Trial registration number: NCT04235205.

Keywords: adult gastroenterology; clinical trials; gastroenterology; hepatobiliary disease.

Conflict of interest statement

Competing interests: Data will be retained in accordance with the Japanese ethical guidelines for clinical research. Participants will be allocated a unique identification (ID) number at entry. The master list linking participant personal information and ID number will be maintained in a separate locked cabinet and password-protected hard drive. Data will be analysed by ID number only. Records will be retained for 5 years after study completion, and then destroyed by the data center. AN reports grants and research support from Gilead, Mylan EPD, EA Pharma, Kowa, Taisho, Biofermin; is a consulting adviser for Gilead, Boehringer Ingelheim, BMS, Kowa, Astellas, EA Pharma, Mylan EPD. Other authors declare no competing interests.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Study design. aN=100 enrolled. CTM, cholestyramine; EXB, elobixibat; NAFLD, non-alcoholic fatty liver disease; PBO, placebo; QD, quaque die.

References

    1. Eguchi Y, Hyogo H, Ono M, et al. . Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol 2012;47:586–95. 10.1007/s00535-012-0533-z
    1. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology 2005;129:375–8. 10.1053/j.gastro.2005.05.041
    1. Musso G, Gambino R, Cassader M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res 2013;52:175–91. 10.1016/j.plipres.2012.11.002
    1. Ferslew BC, Xie G, Johnston CK, et al. . Altered bile acid metabolome in patients with nonalcoholic steatohepatitis. Dig Dis Sci 2015;60:3318–28. 10.1007/s10620-015-3776-8
    1. Aranha MM, Cortez-Pinto H, Costa A, et al. . Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol 2008;20:519–25. 10.1097/MEG.0b013e3282f4710a
    1. Puri P, Daita K, Joyce A, et al. . The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology 2018;67:534–48. 10.1002/hep.29359
    1. Nakajima A, Seki M, Taniguchi S, et al. . Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. Lancet Gastroenterol Hepatol 2018;3:537–47. 10.1016/S2468-1253(18)30123-7
    1. Kumagai Y, Amano H, Sasaki Y, et al. . Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: a randomized controlled trial. Br J Clin Pharmacol 2018;84:2393–404. 10.1111/bcp.13698
    1. Rao A, Kosters A, Mells JE, et al. . Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice. Sci Transl Med 2016;8:357ra122. 10.1126/scitranslmed.aaf4823
    1. Hofmann AF. The syndrome of ileal disease and the broken enterohepatic circulation: cholerheic enteropathy. Gastroenterology 1967;52:752–7. 10.1016/S0016-5085(67)80140-9
    1. Sadik R, Abrahamsson H, Ung K-A, et al. . Accelerated regional bowel transit and overweight shown in idiopathic bile acid malabsorption. Am J Gastroenterol 2004;99:711–8. 10.1111/j.1572-0241.2004.04139.x
    1. Taniai M, Hashimoto E, Tobari M, et al. . Treatment of nonalcoholic steatohepatitis with colestimide. Hepatol Res 2009;39:685–93. 10.1111/j.1872-034X.2009.00507.x
    1. Le T-A, Chen J, Changchien C, et al. . Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012;56:922–32. 10.1002/hep.25731
    1. Mottacki N, Simrén M, Bajor A. Review article: bile acid diarrhoea - pathogenesis, diagnosis and management. Aliment Pharmacol Ther 2016;43:884–98. 10.1111/apt.13570
    1. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. . Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (Flint): a multicentre, randomised, placebo-controlled trial. Lancet 2015;385:956–65. 10.1016/S0140-6736(14)61933-4
    1. Patel J, Bettencourt R, Cui J, et al. . Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2016;9:692–701. 10.1177/1756283X16656735
    1. Imajo K, Kessoku T, Honda Y, et al. . Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology 2016;150:626–37. 10.1053/j.gastro.2015.11.048
    1. Sanyal AJ, Brunt EM, Kleiner DE, et al. . Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011;54:344–53. 10.1002/hep.24376
    1. Sanyal AJ, Friedman SL, McCullough AJ, et al. . Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American association for the study of liver Diseases-U.S. food and drug administration joint workshop. Hepatology 2015;61:1392–405. 10.1002/hep.27678
    1. Ratziu V, Harrison SA, Francque S, et al. . Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology 2016;150:1147–59. 10.1053/j.gastro.2016.01.038
    1. Dulai PS, Sirlin CB, Loomba R. Mri and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J Hepatol 2016;65:1006–16. 10.1016/j.jhep.2016.06.005
    1. Costa-Silva L, Ferolla SM, Lima AS, et al. . Mr elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease. Eur J Radiol 2018;98:82–9. 10.1016/j.ejrad.2017.11.003
    1. Reeder SB, Robson PM, Yu H, et al. . Quantification of hepatic steatosis with MRI: the effects of accurate fat spectral modeling. J Magn Reson Imaging 2009;29:1332–9. 10.1002/jmri.21751
    1. Konerman MA, Jones JC, Harrison SA. Pharmacotherapy for NASH: current and emerging. J Hepatol 2018;68:362–75. 10.1016/j.jhep.2017.10.015
    1. Sanyal A, Charles ED, Neuschwander-Tetri BA, et al. . Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2A trial. Lancet 2019;392:2705–17. 10.1016/S0140-6736(18)31785-9
    1. Harrison SA, Rinella ME, Abdelmalek MF, et al. . NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2018;391:1174–85. 10.1016/S0140-6736(18)30474-4

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다